CL
NBIX icon

Choreo LLC’s Neurocrine Biosciences NBIX Stock Holding History

Choreo LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$472K Sell
3,582
-88
-2% -$11.7K 0.01% 974
2025
Q4 		$517K Sell
3,670
-326
-8% -$47.2K 0.01% 908
2025
Q3 		$561K Sell
3,996
-6
-0.1% -$813 0.01% 871
2025
Q2 		$503K Buy
4,002
+1,298
+48% +$149K 0.01% 890
2025
Q1 		$299K Sell
2,704
-1,061
-28% -$134K ﹤0.01% 1089
2024
Q4 		$516K Buy
3,765
+1,156
+44% +$143K 0.01% 890
2024
Q3 		$298K Buy
2,609
+868
+50% +$119K ﹤0.01% 1207
2024
Q2 		$244K Buy
+1,741
New +$239K ﹤0.01% 1216

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Choreo LLC's NBIX Position: Q1 2026 in Review

Choreo LLC reduced its Neurocrine Biosciences (NBIX) stake by 2.4% in Q1 2026, selling an estimated $11.7K and leaving 3,582 shares worth $472K. The position accounts for 0.01% of the portfolio, ranked #974.

Choreo LLC first reported a position in NBIX in Q2 2024 and has held it in 8 quarters since. The position peaked at $561K in Q3 2025. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Choreo LLC held 3,582 shares of Neurocrine Biosciences worth $472K as of Q1 2026.
  • Choreo LLC sold 88 Neurocrine Biosciences shares in Q1 2026, an estimated $11.7K.
  • Neurocrine Biosciences made up 0.01% of Choreo LLC's portfolio in Q1 2026, its #974 holding.
  • Choreo LLC first reported a position in Neurocrine Biosciences in Q2 2024 and has held it in 8 quarters since.
  • Choreo LLC's Neurocrine Biosciences position peaked at $561K in Q3 2025.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Choreo LLC's 13F filing for Q1 2026, filed 13 May 2026.